Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index; 7 of the 17 sources its claims cite were checked for support.
Abstract
An ultrasmall superparamagnetic iron oxide nanoparticle coupled with Aβ(16–20) and Tat-PTD was developed as a targeted MRI contrast agent to detect Aβ deposits in transgenic mice.
Overview
CoChat Summary
TL;DR
A targeted MRI contrast agent, Tat-PTD-USPIO-Aβ(16-20), was developed by coupling ultrasmall superparamagnetic iron oxide nanoparticles with Tat-PTD and the Aβ(16-20) peptide. It crossed endothelial cell membranes in vitro, bound senile plaques, and decreased T2 MRI signal in APP/PS1 transgenic mice, with no significant toxicity versus control for the coupled agent.
Key findings
- The coupling efficiency was 97.75% for Tat-PTD-USPIO-Aβ(16-20) and 94.62% for Tat-PTD-USPIO-Aβ(1-40); nanoparticles had a core diameter of 6–10 nm, hydration radius ~50 nm, surface charge −8.003 mV, and R2 relaxivity of 140 mmol⁻¹ sec⁻¹.
- In vitro, CMECs incubated with FITC-Tat-PTD-USPIO-Aβ(16-20) showed green fluorescence and potassium ferrocyanide iron staining, indicating membrane penetration; MRI showed decreased T2 signal in cells incubated with the contrast agent.
- Toxicity testing: 20 μM Aβ(1-40) or Aβ(16-20) alone was toxic (n=3; p<0.001), but there was no significant difference for Tat-PTD-USPIO-Aβ(16-20) vs control or Tat-PTD-USPIO vs control; coupling decreased toxicity relative to Aβ(16-20) or Aβ(1-40) alone.
- In vivo, red fluorescence from the contrast agent matched green Thioflavin-S–stained senile plaques, and dark spots on T2-weighted MRI matched these fluorescence distributions in APP/PS1 transgenic mice; no similar spots appeared in wild-type mouse sections.
Methods
- Amino-USPIO nanoparticles were coupled with Tat-PTD and Aβ(16-20) or Aβ(1-40) using EDC/NHS chemistry, ultrafiltration, and BCA protein assays to measure coupling efficiency.
- In vitro studies used primary cultured cerebral microvascular endothelial cells (CMECs) with FITC-Tat-PTD-USPIO-Aβ(16-20) at 0.45 μmol Fe/mL for 48 h, fluorescence microscopy, potassium ferrocyanide staining, 3.0T MRI, and MTT toxicity assays over 72 h with seven groups, including 20 μM Aβ(1-40) or Aβ(16-20).
- In vivo, five APP/PS1 transgenic mice and five age-matched wild-type C57Bl/6J mice (6–8 months old) received tail-vein injections of 0.1 mmol Fe/kg Tat-PTD-USPIO-Aβ(16-20) at 10 μL/s, repeated 24 h later; 7.0T MRI was performed 2 h after the second injection, followed by frozen brain sections (10–20 μm) stained with Thioflavin-S. Statistical analysis used SPSS v13.0 with one-way ANOVA and Student-Newman-Keuls tests, significance at P<0.05, and at least three independent experiments.
Limitations
- Stated: the safety of Tat-PTD was not verified in human subjects because it was obtained from the HIV-1 construct; quantitative experiments are needed to explore statistical differences; and whole-body distribution of the MRI contrast agent should be assessed in future studies.
- Evident from the text: in vivo groups were small (five APP/PS1 transgenic and five wild-type mice), and the MRI/histology findings are largely qualitative, with no quantitative MRI signal analysis reported.
- Evident from the text: no human data are presented; findings are limited to cell culture and a mouse model.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 2 Not valid · 9 Not checked · 33 Own results and interpretations
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“These weaknesses can be overcome with magnetic resonance imaging (MRI).5”
§ Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer's Disease > Introduction
What the sources say
- Could not verifycites [5] Frisoni, 2010, Nat Rev Neurol sourceExperimental — accuracy not yet measured
The ‘Atrophy as a neurodegeneration marker’ section describes structural MRI as measuring atrophy and distinguishes those measures from markers of Aβ deposition. The ‘Conclusions and future perspectives’ section discusses MRI alongside PET amyloid imaging, but does not identify weaknesses of PET plaque imaging or say MRI overcomes them. The available passages have no page numbers. (LLM, conf=0.74)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although senile plaques have been observed with MRI in both postmortem human tissues and AD transgenic mice, 7”
§ Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer's Disease > Introduction
What the sources say
- Partly supportedcites [7] Petiet, 2011, Methods Mol Biol sourceExperimental — accuracy not yet measured
The Introduction says the chapter describes MRI methods for detecting amyloid plaques in vivo and ex vivo in transgenic AD mice. It does not report MRI observation of plaques in postmortem human tissue; its discussion of human plaque imaging instead concerns PET. That human-tissue part of the claim is unsupported by our copy. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Both probes detected Aβ deposits in the brain tissue of APP/PS1 transgenic mice when they were coupled with USPIO particles.”
§ Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer's Disease > Discussion
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The match between red and green fluorescence in one section indicating that the contrast agents bound to the senile plaques in vivo (Figure 4C and D).”
- Also stated in: § Matching in vivo MRI Findings and Histological Studies · hedged
“indicating that this MRI contrast agent bound to senile plaques in APP/PS1 transgenic mice and also decreased the MRI signals (Figure 4B), which was different from the imaging results of the control group.”
§ Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer's Disease > Matching in vivo MRI Findings and Histological Studies
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Matching in vivo MRI Findings and Histological Studies · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the R 2 value of relaxation was 140 mmol -1 sec -1”
§ Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer's Disease > Protein Characterization and Coupling Efficiency
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
21 more claims
Create a free account to see all 49 claims and every source verdict.
- It may state two separate claims as one. 15
- Probably not a substantial claim. 7
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer's Disease > Abstract
“In vitro studies were conducted to measure the coupling efficiency, including bicinchoninic acid protein assays, potassium ferrocyanide staining of cardiac microvascular endothelial cells, 1.5T MRI, and toxicity assessments.”
§ Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer's Disease > In vitro Penetration Studies
“Cells in both groups were washed with phosphate-buffered saline (PBS), collected into Eppendorf tubes, centrifuged at 1000 rpm for 5 min, and imaged with the 3.0T MRI scanner.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer's Disease > 933
“Here we employed PHO (C-IPLPFYN-C) or PHI (C-FRHMTEQ-C) due to their good Aβ affinity.”
§ Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer's Disease > Introduction
“In this study, Aβ (16-20) (KLVFF) was coupled as a probe to bind Aβ deposits, which was the smallest fragment that bound to the fulllength Aβ protein.”
Citations
Cites
Measurement of protein using bicinchoninic acid
Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., & Klenk, D. C. (1985) · Analytical Biochemistry · doi:10.1016/0003-2697(85)90442-7 · Cited by 18,482 · cited 1×
“This method can quantitatively measure solution levels by comparing optical densities (ODs) between unknown and known proteins.(17)”
MethodKarran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188
The clinical use of structural MRI in Alzheimer disease
Frisoni, G. B., Fox, N. C., Jack, C. R., Scheltens, P., & Thompson, P. M. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.215 · Cited by 2,113 · cited 1×
“These weaknesses can be overcome with magnetic resonance imaging (MRI).(5) Models of AD such as transgenic mice can also be used for in vivo studies under high-field MRI.”
BackgroundArrest of -Amyloid Fibril Formation by a Pentapeptide Ligand
Tjernberg, L. O., Näslund, J., Lindqvist, F., Johansson, J., Karlström, A. R., Thyberg, J., Terenius, L., & Nordstedt, C. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.15.8545 · Cited by 963 · cited 1×
“Studies have shown that the binding affinity of Aβ(16–20) is stronger than that of full-length Aβ, which prevents its inclusion into deposits.(12) Moreover, the absence of Aβ(25–35) may decrease contrast agent toxicity.”
BackgroundNeuropathology of Alzheimer's Disease
Perl, D. P. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20157 · Cited by 825 · cited 1×
“Introduction Alzheimer’s disease (AD) is a neurodegenerative disease characterized by chronic progressive dementia, and its hallmark pathological changes include amyloid beta (Aβ) plaques, intracellular neurofibrillary tangles, and neuronal loss.(1) The clinical diagnostic criteria of AD mainly rely on symptoms, scale…”
BackgroundTat peptide-mediated intracellular delivery of pharmaceutical nanocarriers
Torchilin, V. P. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.10.008 · Cited by 449 · cited 1×
“Tat-peptide is one of the most widely used molecules in cellular drug delivery systems.(14) This region consists of 9–16 amino acids that can pass through biological membranes including the BBB.”
BackgroundTAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs
Rao, K. S., Reddy, M. K., Horning, J. L., & Labhasetwar, V. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.08.004 · Cited by 314 · cited 1×
“In our study, the TatPTD construct was used to facilitate entry of the MRI contrast agent past the BBB, similar to the reported ability of CNS delivery in a recent study.(19) Therefore, transport via Tat-PTD is specific due to its coupling with the contrast agent is improved compared with a delivery system where the B…”
MethodEngineered nanoparticles for biomolecular imaging
Mahmoudi, M., Serpooshan, V., & Laurent, S. (2011) · Nanoscale · doi:10.1039/c1nr10326a · Cited by 262 · cited 1×
“Superparamagnetic iron oxide (SPIO) nanoparticles are an MRI contrast agent that can increase the magnetic sensitivity by decreasing the tissue relaxation time and providing real-time images to recognize biological processes at molecular and cellular levels.(9) The ultrasmall SPIO (USPIO) nanoparticles used in the pre…”
BackgroundSPECT and PET imaging in Alzheimer’s disease
Valotassiou, V., Malamitsi, J., Papatriantafyllou, J., Dardiotis, E., Tsougos, I., Psimadas, D., Alexiou, S., Hadjigeorgiou, G., & Georgoulias, P. (2018) · Annals of Nuclear Medicine · doi:10.1007/s12149-018-1292-6 · Cited by 169 · cited 1×
“Positron emission tomography has been employed to visualize Aβ plaques in the brain for the diagnosis of AD,(3) however it has obvious shortcomings, such as radioligand use, limited spatial resolution and higher cost.(4) These weaknesses can be overcome with magnetic resonance imaging (MRI).”
MethodSadowski, M., Pankiewicz, J., Scholtzova, H., Ripellino, J. A., Li, Y., Schmidt, S. D., Mathews, P. M., Fryer, J. D., Holtzman, D. M., Sigurdsson, E. M., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63355-x · Cited by 154 · cited 4×
“The concentration of Aβ(1–40) was 20 μM, which was previously shown to be toxic to CMECs.(18) Accordingly, the concentrations of Aβ(16–20) and bound Aβ(1–40)/Aβ(16–20) in the Tat-PTD -USPIO-Aβ(1–40)/Tat-PTD-USPIO-Aβ(16–20) groups were also set at 20 μM.”
BackgroundInfluentialYang, J., Zaim Wadghiri, Y., Minh Hoang, D., Tsui, W., Sun, Y., Chung, E., Li, Y., Wang, A., de Leon, M., & Wisniewski, T. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.01.023 · Cited by 135
Wadghiri, Y. Z., Li, J., Wang, J., Hoang, D. M., Sun, Y., Xu, H., Tsui, W., Li, Y., Boutajangout, A., Wang, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057097 · Cited by 114
Staffaroni, A., Elahi, F., McDermott, D., Marton, K., Karageorgiou, E., Sacco, S., Paoletti, M., Caverzasi, E., Hess, C., Rosen, H., et al. (2017) · Seminars in Neurology · doi:10.1055/s-0037-1608808 · Cited by 91
Ansciaux, E., Burtea, C., Laurent, S., Crombez, D., Nonclercq, D., Vander Elst, L., & Muller, R. N. (2015) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.1626 · Cited by 42
Magnetic Resonance Imaging of Amyloid Plaques in Transgenic Mouse Models of Alzheimers Disease
Chamberlain, R., M. Wengenack, T., F. Poduslo, J., Garwood, M., & R. Jack, C. (2011) · Current Medical Imaging Reviews · doi:10.2174/157340511794653522 · Cited by 26 · cited 1×
“Unfortunately only a fraction of mature plaques contain sufficient iron, and the long scanning time is not appropriate for in vivo studies.(8) Contrast agents can increase the sensitivity, particularly for smaller Aβ deposits, while also shortening the”
BackgroundTrans-Activating Transcriptional Activator (TAT) Peptide-Mediated Brain Drug Delivery
Rao, K. S., & Labhasetwar, V. (2006) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2006.036 · Cited by 17 · cited 3×
“Many drugs targeting the CNS are limited by the BBB.”
BackgroundInfluentialAndré, S., Ansciaux, E., Saidi, E., Larbanoix, L., Stanicki, D., Nonclercq, D., Elst, L. V., Laurent, S., Müller, R. N., & Burtéa, C. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170563 · Cited by 16
Ma, M., Zhan, Y., Shen, Y., et al. (2011) · Journal of Nanoparticle Research · doi:10.1007/s11051-011-0239-9 · Cited by 15 · cited 3×
“The ultrasmall SPIO (USPIO) nanoparticles used in the present study were functionalized with an amino-group (amino-USPIO), so they could be easily coupled with functional protein.(10) Our preliminary work showed that USPIO nanoparticles coupled with Aβ(1–40) selectively labeled the senile plaques in the brain tissues…”
BackgroundMethodSelf-citationModels of Neurodegenerative Disease – Alzheimer’s Anatomical and Amyloid Plaque Imaging
Petiet, A., Delatour, B., & Dhenain, M. (2011) · Methods in Molecular Biology · doi:10.1007/978-1-61779-219-9_16 · Cited by 14
Carvalho, K. M., França, M. S. F., Camarão, G. C., & Ruchon, A. F. (1997) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x1997001000002 · Cited by 11 · cited 1×
“Moreover, the absence of Aβ(25–35) may decrease contrast agent toxicity.(13) To enhance access through the brain–blood barrier (BBB), we coupled amino-USPIO with the HIV-1 trans-activating”
Method
Research works printed but not linked: 2
- Li, 2011, Zhonghua Yi Xue Za Zhi, 91, 876
- Zhan, 2011, Zhong Hua Shen Jing Ke Za Zhi, 44, 500
Cited by
Ulanova, M., Gloag, L., Bongers, A., Kim, C.-K., Duong, H. T. K., Kim, H. N., Gooding, J. J., Tilley, R. D., Biazik, J. M., Wen, W. X., et al. (2023) · Cells · doi:10.3390/cells12182279 · Cited by 11
“Various ligands, including fluorescent probes [20–22], A β peptides [23–26], antibodies [27–32], as well as hyaluronic acid [33], and lipocalin-type prostaglandin D2 synthase [34], have been employed to target AD pathology, showing promise as potential imaging agents for early diagnosis.”
BackgroundBahman, M., Hosseini, M. R. M., & Jameie, S. B. (2026) · RSC Advances · doi:10.1039/d5ra07458d · Cited by 10
“In recent decades, neuroimaging techniques have been introduced for selective and speci c imaging and monitoring of A b plaque, including magnetic resonance imaging (MRI), 11,12 radiation-based positron emission tomography (PET), 13,14 and single-photon emission-computed tomography (SPECT).”
Molecular Design of Magnetic Resonance Imaging Agents Binding to Amyloid Deposits
Nikiforova, A. A., & Sedov, I. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311152 · Cited by 7
“[199] and in a number of later studies, β-amyloid peptides or their fragments and derivatives were conjugated with gadolinium complexes [200–202] or superparamagnetic iron oxide nanoparticles (SPIONs) [203,204].”
BackgroundShi, Y., Zhang, R., Li, M., Xia, Y., Zhou, M., Cao, R., Zhou, Q., & Zhang, Y. (2026) · Theranostics · doi:10.7150/thno.131311
“Xiong et al. co-conjugated the HIV-1 Tat protein transduction domain (Tat PTD) and the Aβ core recognition fragment Aβ (16-20) to ultrasmall SPIONs [81].”
Metadata
- Authors
- Xiong, Y., Qu, Y., Min, Z., Wu, J., Zhang, S., & Xue, Z.
- Affiliations
- Tongji Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2022-02
- Volume
- Volume 17
- Pages
- 927-936
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- OpenAlex
- W4214734340
- Cited by
- 4
- References
- 20
- Citations by year
- 2026: 2 · 2023: 2
- FWCI
- 0.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Nanomedicine (publishedVersion, cc-by-nc)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Characterization and Applications of Magnetic Nanoparticles
- Keywords
- amyloid-beta imaging, Alzheimer's disease, targeted MRI contrast agents, ultrasmall superparamagnetic iron oxide, blood-brain barrier penetration, transgenic mouse model, contrast agent toxicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.